Description: Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Home Page: werewolftx.com
HOWL Technical Analysis
1030 Massachusetts Avenue
Cambridge,
MA
02138
United States
Phone:
617 952 0555
Officers
| Name | Title |
|---|---|
| Dr. Daniel J. Hicklin Ph.D. | Founder, CEO, Pres, Sec. & Director |
| Mr. Timothy W. Trost CPA | CFO, Treasurer & Assistant Sec. |
| Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer |
| Dr. Reid Leonard Ph.D. | Chief Operating Officer |
| Dr. Cynthia Seidel-Dugan Ph.D. | Chief Scientific Officer |
| Dr. Randi Isaacs M.D. | Chief Medical Officer |
| Ms. Ellen A. Lubman M.B.A. | Chief Bus. Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.4333 |
| Price-to-Book MRQ: | 0.4203 |
| Price-to-Sales TTM: | 6.6088 |
| IPO Date: | 2021-04-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 48 |